Delcath Systems (DCTH) Stock

Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.61 per share a year ago.

Delcath Systems Inc (NASDAQ:DCTH ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, Interventional Oncology Vojislav Vukovic - Chief Medical Officer Conference Call Participants Sudan Loganathan - Stephens Swayampakula Ramakanth - H.C. Wainwright John Newman - Canaccord Genuity Corp Yale Jen - Laidlaw & Company Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings and welcome to the Delcath Systems' Third Quarter 2024 Earnings Call.

Delcath Systems (DCTH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following upcoming investor conferences: Stephens Biotechnology Virtual Fireside Chats Date: Wednesday, November 13, 2024 Fireside Chat Time: 9:30 am Eastern Time Location: Virtual 15th Annual Craig-Hallum Alpha Select Conference Date: Tuesday, November 19, 2024 1.

Delcath Systems (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 8, 2024, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Friday, November.

DCTH's study of the CHEMOSAT Hepatic Delivery System shows that the device significantly boosts survival rates in uveal melanoma patients with liver metastases, outperforming systemic therapies.

Delcath's HEPZATO KIT launch is gaining momentum, setting the company up for a strong 2025. My 2025 sales target is about double the consensus. The stock corrected after the Q2 report due to slower-than-expected hospital formulary acceptances, but Delcath is on track to reach 22 active centers in Q1 2025. ICC and mCRC are the next indications that will cement PHP's position as a platform technology. This will increase Delcath stock's multiple.

Delcath Systems Inc (NASDAQ:DCTH ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, Interventional Oncology Conference Call Participants John Newman - Canaccord Genuity Corp Marie Thibault - BTIG Swayampakula Ramakanth - H.C. Wainwright Sudan Loganathan - Stephens Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to Delcath Systems' Second Quarter 2024 Earnings Conference Call.